The primary goal of this proposal is to characterize the physiological role of the interferon (IFN) regulatory factor-5 (IRF-5) transcription factor in the pathogenesis of systemic lupus erythematosus (SLE). SLE is a chronic systemic autoimmune disease that affects about 0.1% of the US population, and results in inflammation and damage to a range of organ systems. While the primary cause of SLE has not been determined, viral infection or dysfunction of the immune system has been suggested. Several lines of evidence have linked innate immune responses with the pathogenesis of SLE. Plasmacytoid dendritic cells (PDCs) are key mediators of innate immune responses, particularly via their ability to secrete cytokines. They are also the primary source of type I IFN, a molecule important in the front-line defense against viral infection, and recent data suggest that IFN produced by PDCs might be important for SLE pathogenesis. Type I IFNs are remarkable in their ability to prime further IFN production, which is likely to occur through the IFN regulatory factors, such as IRF-3, IRF-5, and IRF-7. Recent data indicate that polymorphism within the IRF-5 gene is associated with SLE; single-nucleotide polymorphisms (SNPs) were identified in the IRF-5 gene that displayed strong signals in joint analysis of linkage and association with SLE. IRF-5 is constitutively expressed mainly in cells of the immune system, particularly in PDC, monocytes, monocytederived dendritic cells, as well as in B cells. With the recent identification of multiple alternatively spliced IRF- 5 isoforms, each with distinct cell type-specific expression, regulation, and function, it is reasonable to suggest that polymorphism within IRF-5 may affect several cellular functions of importance for the development of an autoimmune disease such as SLE. As such, we hypothesize that alterations in IRF-5 isoform expression and function play an important role in SLE pathogenesis associated with the elevated levels of type I IFNs in the serum of SLE patients. The following specific aims have been designed to test this hypothesis, 1) Characterization of IRF-5 isoform expression associated with the pathogenesis of SLE, and 2) Determination of the physiological significance of IRF-5 polymorphism associated with SLE. Results from these studies will provide new insight into our understanding the physiological role for IRF-5 in the autoimmune and pathological phenomena of SLE. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Research Grants (R03)
Project #
1R03AR054070-01
Application #
7139435
Study Section
Special Emphasis Panel (ZAR1-EHB-J (M1))
Program Officer
Mancini, Marie
Project Start
2006-09-07
Project End
2009-06-30
Budget Start
2006-09-07
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$77,750
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Biochemistry
Type
Schools of Medicine
DUNS #
623946217
City
Newark
State
NJ
Country
United States
Zip Code
07107
Korczeniewska, Justyna; Barnes, Betsy J (2018) Corrected and Republished from: The COP9 Signalosome Interacts with and Regulates Interferon Regulatory Factor 5 Protein Stability. Mol Cell Biol 38:
Korczeniewska, Justyna; Barnes, Betsy J (2013) The COP9 signalosome interacts with and regulates interferon regulatory factor 5 protein stability. Mol Cell Biol 33:1124-38
Stone, Rivka C; Du, Peicheng; Feng, Di et al. (2013) RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE. PLoS One 8:e54487
Feng, Di; Yang, Lisong; Bi, Xiaohui et al. (2012) Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur J Immunol 42:1477-87
Yang, Lisong; Feng, Di; Bi, Xiaohui et al. (2012) Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus. J Immunol 189:3741-50
Stone, Rivka C; Feng, Di; Deng, Jing et al. (2012) Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons. Arthritis Rheum 64:788-98
Feng, Di; Sangster-Guity, Niquiche; Stone, Rivka et al. (2010) Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 185:6003-12
Feng, Di; Stone, Rivka C; Eloranta, Maija-Leena et al. (2010) Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 62:562-73
Sigurdsson, Snaevar; Goring, Harald H H; Kristjansdottir, Gudlaug et al. (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17:872-81